Bristol-Myers Squibb has extended its strategic partnership for TARGET-NASH to a new multi-year agreement. Bristol-Myers Squibbis committed to the discovery and development of medicines for fibrosis, including NASH. The study will enroll up to 15,000 patients over the coming years.
https://www.prnewswire.com/news-releases/bristol-myers-squibb-bmy-extends-strategic-partnership-with-target-pharmasolutions-for-target-nash-300535524.html
